ICD-10 Codes Don't Tell the Full Story About Heart Failure | AHA Scientific Sessions

A post-hoc analysis of the SCORED clinical trial identified early benefit for patients taking Inpefa in both heart failure and major adverse cardiovascular events (MACE) related outcomes

Researchers reported positive results at the AHA meeting today from a small, 48-patient study of lepodisiran, a short interfering RNA therapy designed to reduce lipoprotein(a) levels.

An analysis estimated the clinical and economic impact of Inpefa using inputs from a phase 3 trial of the heart failure drug.

Ten patients have been treated with the CRISPR-based gene therapy, the drug developer's chief scientific officer announced today, and high doses have had the intended effect of lowering LDL cholesterol. One study volunteer died five weeks after the infusion from cardiac arrest, but the company says the death was unrelated to the therapy and no changes were made to the study.

A study that randomized villages in China to an intensive blood pressure-lowering program or usual care showed a 15% decrease in all-cause dementia from the program.

In a phase 2 trial, abelacimab achieved a 99% inhibition of Factor XI and a 67% reduction in major or clinically relevant non-major bleeding events.